TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Macrophage colony forming units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevention of relapse or recurrence of depressive disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of S-PCT compared to TAU
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Expiratory peak flow (EPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in depressive disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AF lasting more than 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: symptomatic AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antidepressant efficacy (HAM-D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiolytic activity (COVI, STAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agitation (HAM-D Agitation item)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychic Anxiety (Psychic Anxiety item)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Demodex folliculorum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen saturation values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional Outcomes of Sleep Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mean daily hours of CPAP adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bronchodilator responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: scrotal edema incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of retrieved oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum E2 levels on HCG injection day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum E2 levels on oocyte retrieval day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Antral filling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Placement in supervised settings
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Care needs met
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Loss of autonomy from physical disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-care productivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of developing obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Odds of developing overweight or obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HER2 overexpression and/or amplification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Manual Function Test (MFT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: guideline adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily milk volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapeutic failures
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of cochlear or renal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: decreased anxiety posttreatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decreased depression posttreatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Foot posture index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required for navicular height to reach minimum value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for intubation of a given ostium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for retrieval of a foreign body from the tracheobronchial system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent PASI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvements in BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median 4-week migraine rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: At least 50% reduction in 4-week migraine rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of days per 4 weeks with migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: true sleep duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attrition rate among CHWs
Endpoint domain: Adverse events/effects
Primary endpoint: Mean strength values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean delay in GI motility recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of postoperative ileus
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of sodium nitroprusside used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain palliation response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Absorption Time (MAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in C3M levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CRPM levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of ACR20 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infection incidence of the pin hole
Endpoint domain: Adverse events/effects
Primary endpoint: skin microcirculatory perfusion flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to control blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily average insulin dosage reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of PCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall success rate of intravenous cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average procedure duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of early leukocytosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median WBC count 24 h after pegfilgrastim administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median WBC count at day 13
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Circulating concentrations of choline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative narcotic consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-Q wave myocardial infarction rate
Endpoint domain: Adverse events/effects
Primary endpoint: angiographic restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: gain in minimal lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Loss of visual reading ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores of SDGDS, SAS, and BDI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of high quality oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Total glucose area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rhinitis global scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma global scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of positive response on the Clinical Global Impressions, Improvement subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score reduction on the Children's Yale‐Brown Obsessive Compulsive Scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events associated with citalopram use
Endpoint domain: Adverse events/effects
Primary endpoint: P(aO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chewing comfort improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: annual HbA1c testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: annual eye examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: annual lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Optimal LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Preference for IL 200 pen over IL 100 pen
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fear of recurrence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mindfulness attitude
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: abstinent days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perioperative normothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nerve function improvement (NIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: TSS in the feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative primary composite endpoint at 4-week follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression (HAMD score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea and vomiting (INVR score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of morning ACTH and cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in HRQoL indices in the vitality domain
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: daily stepping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade >or=3 gastrointestinal and hematologic toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Microbiologic eradication and clinical cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with the medication regimen
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Peak serum concentrations (Cmax) of simvastatin and simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Areas under the serum concentration‐time curve (AUC(0‐infinity)) of simvastatin and simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (t1/2) of simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of sites with PD≥6mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in sVEGFR2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measurable declines in serum CTx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of death within 60 days
Endpoint domain: Mortality/survival
Primary endpoint: continence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion achieving 4-SU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 3-year postoperative all-items ratios of UCLP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year postoperative CPH and ULH ratio of UCL/UCLA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-controlled morphine analgesia usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active assisted knee flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: State-Trait Anxiety Inventory - State (STAI-S)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: State-Trait Anxiety Inventory - Trait (STAI-T)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Papilla index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical outcomes after reperfusion therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Entrainment of circadian rhythms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent awake after initial onset of sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative delirium (PD)
Endpoint domain: Mortality/survival
Primary endpoint: Preoperative pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fentanyl consumption before surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of MLPT at detecting absence of continuing pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Positive predictive value of MLPT at detecting continuing pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Hospital Anxiety and Depression Scale - Total (HADS-T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Care home admission
Endpoint domain: Mortality/survival
Primary endpoint: Functional balance assessed by Berg scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver burden assessed by Neuropsychiatric Inventory and Zarit scale
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Time to ovulation after ring removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Median time to develop a follicle up to 13 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rigid erection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous detumescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged erection
Endpoint domain: Adverse events/effects
Primary endpoint: decrease in fasting plasma glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: KOOS pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Knee Replacement (TKR) frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Insulin suppression of AT lipolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bile leakage incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Spherical Equivalent Refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Corneal Curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-operation due to complications
Endpoint domain: Adverse events/effects
Primary endpoint: Medical care utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement of social functions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of teleconsultations per quarter
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response rate based on YMRS and CGI-I scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate based on YMRS and CGI severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FTN task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean long-term IOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: propofol injection pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LDL cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of post/predialysis concentration ratio (over 1.5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in peak torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: type I fiber cross‐sectional area (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: myonuclear domain of type II muscle fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean bleeding on probing reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical attachment level gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in cognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of new onset T2DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Function ability scores in the Wolf Motor Function Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAP increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnoea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CLAD prevalence
Endpoint domain: Mortality/survival
Primary endpoint: Institutionalization
Endpoint domain: Mortality/survival
Primary endpoint: Sense of competence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Facial Disability Index-social
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: relief of headache, nausea, and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interval between treatment and relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmation of depression diagnosis and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month height SDS gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in reexperiencing symptoms (CAPS-B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in avoidance/numbing symptoms (CAPS-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in CAPS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale-Brown Obsessive-Compulsive Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to arrhythmia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neurologically intact survival to hospital discharge
Endpoint domain: Mortality/survival
Primary endpoint: Stress levels measured by PSS-10 scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increased time of sun exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VISA-A score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knowledge on additives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital bed days used
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Need for antiemetic and antipruritic medications
Endpoint domain: Adverse events/effects
Primary endpoint: HIV acquisition protection
Endpoint domain: Mortality/survival
Primary endpoint: Quantification of proteins in bronchial biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of UTI prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal surgical conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in SGRQ‐TS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CYP2D6 disinhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes